Jasper Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising efficacy results from Jasper Therapeutics’ trials, despite recent setbacks. The company faced a drug lot issue affecting certain doses in their BEACON trial, but they have taken steps to address the problem by investigating the cause and continuing the trial with a new drug lot. Importantly, there were no safety concerns, and the trial is expected to proceed without patient discontinuation.
Moreover, the efficacy of the 240 mg and 360 mg doses has been consistently positive, with a significant number of patients experiencing a reduction in serum tryptase and achieving complete responses. The durability of these responses supports the dosing schedule and indicates a strong potential for the drug’s effectiveness. These factors contribute to Bodnar’s confidence in the company’s prospects, justifying the Buy rating despite the temporary delay in the trial timeline.
According to TipRanks, Bodnar is an analyst with an average return of -6.5% and a 29.30% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Agenus, and NovoCure.